QRXPHARMA LTD (ASX:QRX)
http://www.qrxpharma.com
Industry: Pharmaceuticals, Biotechnology and Life Sciences
Activity: The Company is a clinical stage specialty pharmaceutical company focused on developing and commercialising therapies to treat disorders of the central nervous system.
194 Miller Street Level 1 NORTH SYDNEY NSW 2060
Ph: (02) 9492 8021    Fax: (02) 8920 0314

No broadcast is found.

Icon_lastIcon_nextIcon_previousIcon_first
Annual General Meeting
Mon, 4 Nov 2013
Interim Results
Mon, 18 Feb 2013
Annual General Meeting
Wed, 7 Nov 2012
Interim Results
Fri, 24 Feb 2012
Annual General Meeting
Wed, 16 Nov 2011
Full Year Results
Mon, 22 Aug 2011
Quarterly Sales Date
Thu, 28 Apr 2011
Interim Results
Tue, 22 Feb 2011
Annual General Meeting
Mon, 8 Nov 2010
Annual General Meeting
Mon, 16 Nov 2009 11:00am
Click here to view details on the ASX site
Appendix 3B - Exercise of Stock Options Wed, 5 Jun 2013
FDA sets 17 July 2013 for MOXDUO Advisory Committee Meeting Fri, 17 May 2013
Appendix 3B - Exercise of Stock Options Thu, 9 May 2013
Appendix 4C - Quarter Ended 31 March 2013 Mon, 29 Apr 2013
FDA sets 26 August 2013 as new PDUFA date for MOXDUO NDA Thu, 14 Mar 2013
Investor Presentation Update - March 2013 Fri, 1 Mar 2013
QRxPharma Resubmits MOXDUO New Drug Application to the FDA Thu, 28 Feb 2013
Appendix 3B - Option Issue Thu, 21 Feb 2013
Investor Presentation Update - February 2013 Mon, 18 Feb 2013
Half Yearly Report and Accounts - 31 December 2012 Mon, 18 Feb 2013

Please note: This company appears on this website as a result of its listing on the Australian Securities Exchange. BRR Media does not claim any association with any company listed on this site.